Cargando…

Case Report: A case of complete response to entrectinib in NTRK fusion gene-positive parotid gland cancer

INTRODUCTION: Expression of the NTRK gene is rare in solid tumors but is highly prevalent in salivary gland secretory carcinomas. Here, we report a case of a complete response to entrectinib in a patient with NTRK fusion gene-positive parotid carcinoma. CASE DESCRIPTION: The patient was a 44-year-ol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moriyama, Etsuko, Nagasu, Sachiko, Tanaka, Toshimitsu, Shimotsuura, Yasutaka, Ono, Takeharu, Umeno, Hirohito, Akiba, Jun, Kawahara, Akihiko, Fujita, Fumihiko, Kawaguchi, Takumi, Miwa, Keisuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436465/ https://www.ncbi.nlm.nih.gov/pubmed/37601665 http://dx.doi.org/10.3389/fonc.2023.1247435

Ejemplares similares

Safety of Early Bevacizumab Administration after Central Venous Port Placement for Patients with Colorectal Cancer
por: Shigyo, Hirona, et al.
Publicado: (2023)

Changes in immune parameters between pre-treatment and recurrence after (chemo) radiation therapy in patients with head and neck cancer
por: Ono, Takeharu, et al.
Publicado: (2020)

Entrectinib demonstrates prolonged efficacy in an adult case of radiation-refractory NTRK fusion glioblastoma
por: Grogan, Patrick T, et al.
Publicado: (2022)

Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
por: Frampton, James E.
Publicado: (2021)

Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment
por: Sato, Fumihiko, et al.
Publicado: (2019)

MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements
por: Takumi, Yohei, et al.
Publicado: (2022)

Case report: Changes in serum bevacizumab concentration in a hemodialysis patient with unresectable colorectal cancer treated with FOLFIRI plus bevacizumab
por: Tanaka, Toshimitsu, et al.
Publicado: (2022)

Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1‐rearranged tumor cells
por: Suzuki, Chiaki, et al.
Publicado: (2022)

Correction to: Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
por: Frampton, James E.
Publicado: (2021)

Response to entrectinib in a malignant glioneuronal tumor with ARHGEF2-NTRK fusion
por: Kurozumi, Kazuhiko, et al.
Publicado: (2022)

The experience of successful treatment of ETV6-NTRK3-positive infant glioblastoma with entrectinib
por: Papusha, Ludmila, et al.
Publicado: (2021)

Entrectinib Induces Apoptosis and Inhibits the Epithelial–Mesenchymal Transition in Gastric Cancer with NTRK Overexpression
por: Sohn, Sung-Hwa, et al.
Publicado: (2021)

Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion
por: Dunn, Danielle B.
Publicado: (2020)

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
por: Farago, Anna F., et al.
Publicado: (2015)

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
por: Demetri, George D., et al.
Publicado: (2022)

Association between PD-L1 expression combined with tumor-infiltrating lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma
por: Ono, Takeharu, et al.
Publicado: (2017)

Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib
por: Lazzari, Chiara, et al.
Publicado: (2022)

Entrectinib for NTRK Fusion-Positive Metastatic Melanoma Progressing on Combined PD-1 and CTLA-4 Inhibition: A Case Report
por: Dawood, Shaheenah, et al.
Publicado: (2023)

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2015)

Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies
por: Ardini, Elena, et al.
Publicado: (2020)

Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion–Positive Solid Tumors
por: Demetri, George D., et al.
Publicado: (2022)

NTRK3 mutation in secretory carcinoma of the parotid gland: A Case report
por: AlKaabba, Fahad, et al.
Publicado: (2022)

Entrectinib use in a platinum-refractory mucinous ovarian cancer harboring a NTRK3 gene fusion
por: Beck, Olivia G., et al.
Publicado: (2023)

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
por: Liu, Dazhi, et al.
Publicado: (2018)

Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated ROS1/NTRK-Fusion Positive Pediatric High-Grade Glioma
por: Mayr, Lisa, et al.
Publicado: (2020)

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
por: Desai, Ami V, et al.
Publicado: (2022)

Mucoepidermoid carcinoma of the sublingual gland harboring a translocation of the MAML2 gene: A case report
por: Sato, Kiminobu, et al.
Publicado: (2017)

Development of Neuropathic Arthropathy With Entrectinib: Case Report
por: Giustini, Nicholas P., et al.
Publicado: (2022)

Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib
por: Dziadziuszko, Rafal, et al.
Publicado: (2022)

ETV6–NTRK3-positive parotid mammary analogue secretory carcinoma: a case report
por: Cobo, Juan Rodríguez, et al.
Publicado: (2021)

Clinicopathological investigation of secretory carcinoma cases including a successful treatment outcome using entrectinib for high-grade transformation: a case report
por: Suzuki, Kensuke, et al.
Publicado: (2022)

In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)
por: Meneses-Lorente, Georgina, et al.
Publicado: (2021)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
por: Wang, Jiao‐Li, et al.
Publicado: (2022)

Profiles Combining Muscle Atrophy and Neutrophil-to-Lymphocyte Ratio Are Associated with Prognosis of Patients with Stage IV Gastric Cancer
por: Shigeto, Kota, et al.
Publicado: (2020)

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
por: Drilon, A., et al.
Publicado: (2016)

Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report
por: Damásio, Inês, et al.
Publicado: (2022)

Heterogeneity and hierarchy of the tissue stem cells in the human newborn vocal fold mucosa
por: Sato, Kiminori, et al.
Publicado: (2020)

Histopathology of maxillary sinus mucosa with odontogenic maxillary sinusitis
por: Sato, Kiminori, et al.
Publicado: (2020)

Glycolytic activity of the tissue stem cells in the macula flava of the human vocal fold
por: Sato, Kiminori, et al.
Publicado: (2021)

Role of colony‐forming tissue stem cells in the macula flava of the human vocal fold in vivo
por: Sato, Kiminori, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_srh71f776f6qdf2liv8h30nrua